Results of a phase II study of brentuximab vedotin using a response adapted design for first line treatment of patients with Hodgkin lymphoma who were unsuitable for chemotherapy due to age, frailty or co-morbidity

Adam Gibb, Sarah Pirrie, Kim Linton, Kathryn Paterson, Andrew Davies, Graham P. Collins, Tobias Menne, Pamela McKay, Paul Fields, Fiona Miall, Eszter Nagy, Keith Wheatley, Keith Wheatley, Sally Barrington, John Radford

Research output: Chapter in Book/Report/Conference proceedingConference contributionpeer-review

Original languageEnglish
Title of host publication. Results of a phase II study of brentuximab vedotin using a response adapted design for first line treatment of patients with Hodgkin lymphoma who were unsuitable for chemotherapy due to age, frailty or co-morbidity
PublisherFerrata Storti Foundation
Publication statusPublished - 2016
Event10th International Symposium for Hodgkin Lymphoma (ISHL) - Cologne, Germany
Duration: 22 Oct 201625 Oct 2016
Conference number: 10

Conference

Conference10th International Symposium for Hodgkin Lymphoma (ISHL)
Abbreviated titleISHL
Country/TerritoryGermany
CityCologne
Period22/10/1625/10/16

Keywords

  • Hodgkin lymphoma
  • Brentuximab vedotin
  • Antibody drug conjugate
  • Elderly
  • Frail

Research Beacons, Institutes and Platforms

  • Cancer
  • Manchester Cancer Research Centre

Cite this